Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF V600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Titel:
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF V600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Auteur:
Ascierto, Paolo A Stroyakovskiy, Daniil Gogas, Helen Robert, Caroline Lewis, Karl Protsenko, Svetlana Pereira, Rodrigo P Eigentler, Thomas Rutkowski, Piotr Demidov, Lev Zhukova, Natalia Schachter, Jacob Yan, Yibing Caro, Ivor Hertig, Christian Xue, Cloris Kusters, Lieke McArthur, Grant A Gutzmer, Ralf